Gregory H. Bailey - 20 Aug 2024 Form 4 Insider Report for Serina Therapeutics, Inc. (SER)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Aug 2024, 17:27:27 UTC
Prior SEC filing
20 Aug 2024
Next SEC filing
20 Sep 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Gregory Bailey

Key filing fact

Gregory H. Bailey filed Form 4 for Serina Therapeutics, Inc. (SER) on 22 Aug 2024.

Key facts

  • This page summarizes Gregory H. Bailey's Form 4 filing for Serina Therapeutics, Inc. (SER).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 22 Aug 2024, 17:27.

Change

  • Previous filing in this sequence was filed on 20 Aug 2024.
  • Current net transaction value: +$14,652.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SER transaction

Common Stock

Purchase

Transaction value
$14,652
Shares
+1,776
Change %
+3.9%
Price
$8.25
Shares after
47,582
Date
20 Aug 2024
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reflects the weighted average purchase price of multiple transactions ranging from a low of $8.00 per share to a high of $8.88 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .